CI, confidence interval
Cardiovascular events, such as cardiac arrhythmias, may be seen after the administration of muscarinic recepter antagonists and sympatho-mimetic agents, including umeclidinium/vilanterol. Therefore, Anoro Ellipta should be used with caution in patients with severe cardiovascular disease. 2
**Trough FEV1 improved by 180mL for Anoro (n=225) vs. 128mL for Tiotropium/Olodaterol(n=224) at week 8, in the ITT population; difference 52mL (95% CI: 28, 77; p<0.001) 1
†Reduced by 0.94 puffs/day for Anoro (n=222) vs. 0.68 puffs/day for Tiotropium/Olodaterol(n=217); difference in change from baseline with Anoro vs. Tiotropium/Olodaterol -0.25 (95% CI: -0.37, -0.14; p<0.001) 1
††Maintenance naïve: Patients who had not received a maintenance treatment (LAMA, LABA alone or in combination ± ICS) for COPD in the 30 days that records were kept prior to screening.
†††Post-hoc subgroup analysis at Week 8 in maintenance-naïve patients (n=148; 167mL vs. 110mL, Δ57mL; p=0.001)
Trade marks are owned by or licensed to the GSK group of companies.